Category: Insulet Corp.
Diabetes devices maker Insulet posts a stellar quarter that beats Wall Street's expectations and notes a pending Massachusetts Attorney General inquiry.
Massachusetts-based Insulet (NSDQ:PODD) got some Wall Street love today after posing a significant bump in sales for its 4th quarter and the full year of 2013.
Insulet plans an expansion into new headquarters, moving from Bedford, Mass., to nearby Billerica.
Insulet (NSDQ:PODD) is moving its corporate headquarters to Billerica, Mass., 9 minutes away from the company's current home in Bedford, Mass.
Insulin pump maker Insulet plans to add another 20 sales reps to its team by the end of Q1, as the company continues to see major growth in pediatric users of its tubeless OmniPod system.
Insulet (NSDQ:PODD) president & CEO Duane DeSisto is looking for a few good reps, planning to add 20 members to the company's sales force by the end of the 1st quarter.
Neuro Kinetics named former Zoll Medical executive Michael Saporito as CFO.
Neuro Kinetics appointed Michael Saporito as its new CFO.
Saporito joins the Pittsburgh-based medical device company after years with LifeVest, which he helped turn around before the company was bought out by Zoll Medical.
Insulin pump maker Insulet and biotech company Amgen plan a 5-year partnership for biotechnology medicine delivery devices.
Insulet misses the mark with its 3rd-quarter sales and earnings results and tightens its revenue forecast for the rest of the year.
Insulet (NSDQ:PODD) fell short of Wall Street's expectations with its 3rd-quarter results, missing the mark for both sales and earnings and tightening its revenue outlook for the rest of 2013.
Insulet Corp. hires the former director of Clinical Research & Technology for the Sansum Diabetes Research Institute, Dr. Howard Zisser, as its 1st medical director.
Insulet (NSDQ:PODD) said it named Dr. Howard Zisser, the former clinical director of the Sansum Diabetes Research Institute, as its 1st medical director.
Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.